Crinetics Pharmaceuticals, Inc.

NasdaqGS:CRNX

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

💊 Pharmaceuticals

Location

United States

Market Cap

USD 2.90 B

Share Price

USD 30.41

Avg Daily Volume

983,211

Change (1 day)

-1.71%

Change (1 year)

-32.23%

Change (YTD)

-40.52%

Crinetics Pharmaceuticals, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending March 31, 2025: USD 0.00

Crinetics Pharmaceuticals, Inc. Dividends Paid is USD 0.00 for the Trailing 12 Months (TTM) ending March 31, 2025. Dividends paid is cash paid to shareholders as a distribution of profits.

Crinetics Pharmaceuticals, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 0.00.
Crinetics Pharmaceuticals, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 0.00.
Crinetics Pharmaceuticals, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 0.00.
Crinetics Pharmaceuticals, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 0.00.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Dividends Paid	Common Stock Issued	Common Stock Repurchased	Free Cash Flow

NasdaqGS: CRNX

Crinetics Pharmaceuticals, Inc.

CEO	Dr. R. Scott Struthers Ph.D.
IPO Date	July 18, 2018
Location	United States
Headquarters	Building No. 2
Employees	437
Sector	🏥 Health Care
Industries Clinical Trials 💊 Pharmaceuticals

Description

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as well as completed phase II clinical trial to treat carcinoid syndrome and nonfunctional neuroendocrine tumors (NETs). The company is also developing CRN04777, an oral selective nonpeptide somatostatin type 5 receptor agonist, which is in phase I clinical trial for the treatment of congenital hyperinsulinism; and CRN04894, an oral adrenocorticotrophic hormone antagonist that is in phase I clinical trial for the treatment of Cushing's and congenital adrenal hyperplasia diseases. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.